The use of melittin to enhance transgene expression mediated by recombinant adeno-associated virus serotype 2 vectors both in vitro and in vivo

被引:9
作者
Xie, Yi-lin [1 ,2 ]
Wang, Ji-yao [1 ,2 ,3 ,4 ]
He, Yun [1 ,2 ]
Yu, Xiao-min [3 ,4 ]
Zheng, Qing-yun [1 ,2 ]
Ling, Chen [1 ,2 ,3 ,4 ]
Feng, Xi-lin [1 ,2 ,5 ]
Zhu, Li-qing [3 ,4 ]
机构
[1] Fudan Univ, Sch Life Sci, Zhongshan Hosp, State Key Lab Genet Engn, Shanghai 200438, Peoples R China
[2] Fudan Univ, Sch Life Sci, Zhongshan Hosp, Engn Res Ctr Gene Technol Minist Educ, Shanghai 200438, Peoples R China
[3] Wenzhou Med Univ, Dept Clin Lab, Affiliated Hosp 1, Wenzhou 325000, Zhejiang Provin, Peoples R China
[4] Key Lab Clin Lab Diag & Translat Res Zhejiang Pro, Wenzhou 325000, Zhejiang Provin, Peoples R China
[5] Yantai Fuheng Biol Technol Co Ltd, Yantai 264006, Shandong Provic, Peoples R China
来源
JOURNAL OF INTEGRATIVE MEDICINE-JIM | 2023年 / 21卷 / 01期
基金
中国国家自然科学基金;
关键词
rAAV; Melittin; Capsid engineering; Co; -administration; Transduction efficiency; CELL-PENETRATING PEPTIDES; HIGH-AFFINITY LIGANDS; AAV2 CAPSID GENE; TRANSDUCTION EFFICIENCY; TRANSFECTION; MUTAGENESIS; ADENOVIRUS; DELIVERY; SURFACE; BRAIN;
D O I
10.1016/j.joim.2022.10.003
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Objective: Melittin, a cell-penetrating peptide, improves the efficiency of many non-viral gene delivery vectors, yet its application in viral vectors has not been well studied. The non-pathogenic recombinant adeno-associated virus (rAAV) vector is an ideal in vivo gene delivery vector. However, its full potential will only be achieved after improvement of its transduction efficiency. To improve the transduction effi-ciency of rAAV2 vectors, we attempted to develop a melittin-based rAAV2 vector delivery strategy. Methods: The melittin peptide was inserted into the rAAV2 capsid either in the loop VIII of all viral pro-teins (VPs) or at the N terminus of VP2. Various rAAV2-gfp or -fluc vectors were subjected to quantitative real-time polymerase chain reaction and Western blot assays to determine their titers and integrity of capsid proteins, respectively. Alternatively, the vectors based on wild-type capsid were pre-incubated with melittin, followed by transduction of cultured cells or tail vein administration of the mixture to C57BL/6 and BALB/c nude mice. In vivo bioluminescence imaging was performed to evaluate the trans -gene expression. Results: rAAV2 vectors with melittin peptide inserted in the loop VIII of VPs had low transduction effi-ciency, probably due to dramatically reduced ability to bind to the target cells. Fusing the melittin peptide at the N-terminus of VP2 produced vectors without the VP2 subunit. Interestingly, among the commonly used rAAV vectors, pre-incubation of rAAV2 and rAAV6 vectors with melittin significantly enhanced their transduction efficiency in HEK293 and Huh7 cells in vitro. Melittin also had the ability to increase the rAAV2-mediated transgene expression in mouse liver in vivo. Mechanistically, melittin did not change the vector-receptor interaction. Moreover, cell counting kit-8 assays of cultured cells and serum transam-inase levels indicated melittin had little cytotoxicity. Conclusion: Pre-incubation with melittin, but not insertion of melittin into the rAAV2 capsid, significantly enhanced rAAV2-mediated transgene expression. Although further in vivo evaluations are required, this research not only expands the pharmacological potential of melittin, but also provides a new strategy to improve gene therapy mediated by rAAV vectors. Please cite this article as: Xie YL, Wang JY, He Y, Yu XM, Zheng QY, Ling C, Feng XL, Zhu LQ. The use of melittin to enhance transgene expression mediated by recombinant adeno-associated virus serotype 2 vectors both in vitro and in vivo. J Integr Med. 2023; 21(1): 106-116. (c) 2022 Shanghai Yueyang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. All rights reserved.
引用
收藏
页码:106 / 116
页数:11
相关论文
共 38 条
  • [1] BioMarin Pharmaceuticals, 2021, US FDA PLAC CLIN HOL
  • [2] Melittin analogs with high lytic activity at endosomal pH enhance transfection with purified targeted PEI polyplexes
    Boeckle, Sabine
    Fahrmeir, Julia
    Roedl, Wolfgang
    Ogris, Manfred
    Wagner, Ernst
    [J]. JOURNAL OF CONTROLLED RELEASE, 2006, 112 (02) : 240 - 248
  • [3] Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors
    Buning, Hildegard
    Srivastava, Arun
    [J]. MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2019, 12 : 248 - 265
  • [4] Synthetic PEGylated glycoproteins and their utility in gene delivery
    Chen, Chang-po
    Kim, Ji-seon
    Liu, Dijie
    Rettig, Garrett R.
    McAnuff, Marie A.
    Martin, Molly E.
    Rice, Kevin G.
    [J]. BIOCONJUGATE CHEMISTRY, 2007, 18 (02) : 371 - 378
  • [5] Deleterious effect of peptide insertions in a permissive site of the AAV2 capsid
    Douar, AM
    Poulard, K
    Danos, O
    [J]. VIROLOGY, 2003, 309 (02) : 203 - 208
  • [6] Finkel RS, 2014, NEUROLOGY, V83, P810, DOI 10.1212/WNL.0000000000000741
  • [7] Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial
    Gaudet, D.
    Methot, J.
    Dery, S.
    Brisson, D.
    Essiembre, C.
    Tremblay, G.
    Tremblay, K.
    de Wal, J.
    Twisk, J.
    van den Bulk, N.
    Sier-Ferreira, V.
    van Deventer, S.
    [J]. GENE THERAPY, 2013, 20 (04) : 361 - 369
  • [8] Site-specific modifications to AAV8 capsid yields enhanced brain transduction in the neonatal MPS IIIB mouse
    Gilkes, Janine A.
    Judkins, Benjamin L.
    Herrera, Brontie N.
    Mandel, Ronald J.
    Boye, Sanford L.
    Boye, Shannon E.
    Srivastava, Arun
    Heldermon, Coy D.
    [J]. GENE THERAPY, 2021, 28 (7-8) : 447 - 455
  • [9] Gene therapy clinical trials worldwide to 2017: An update
    Ginn, Samantha L.
    Amaya, Anais K.
    Alexander, Ian E.
    Edelstein, Michael
    Abedi, Mohammad R.
    [J]. JOURNAL OF GENE MEDICINE, 2018, 20 (05)
  • [10] Treatment of Leber Congenital Amaurosis Due to RPE65 Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I Trial
    Hauswirth, William W.
    Aleman, Tomas S.
    Kaushal, Shalesh
    Cideciyan, Artur V.
    Schwartz, Sharon B.
    Wang, Lili
    Conlon, Thomas J.
    Boye, Sanford L.
    Flotte, Terence R.
    Byrne, Barry J.
    Jacobson, Samuel G.
    [J]. HUMAN GENE THERAPY, 2008, 19 (10) : 979 - 990